Allena Pharmaceuticals, Inc. Net Debt/EBITDA

Net Debt/EBITDA of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt/EBITDA growth rates and interactive chart.


Highlights and Quick Summary

  • Net Debt/EBITDA for the quarter ending March 31, 2022 was 0.78 (a -60.68% decrease compared to previous quarter)
  • Year-over-year quarterly Net Debt/EBITDA decreased by -36.24%
  • Annual Net Debt/EBITDA for 2021 was 0.42 (a -46.76% decrease from previous year)
  • Annual Net Debt/EBITDA for 2020 was 0.79 (a 88.09% increase from previous year)
  • Annual Net Debt/EBITDA for 2019 was 0.42 (a -71.31% decrease from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt/EBITDA of Allena Pharmaceuticals, Inc.

Most recent Net Debt/EBITDAof ALNA including historical data for past 10 years.

Interactive Chart of Net Debt/EBITDA of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.78
2021 1.98 2.47 1.22 2.32 0.42
2020 2.56 2.55 2.79 1.48 0.79
2019 1.74 2.4 3.54 3.67 0.42
2018 5.3 6.25 8.47 10.29 1.45
2017 13.58 6.28 0.0 0.0 4.08
2016 0.0 1.63
2015 0.0 4.71

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.